<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00804921</url>
  </required_header>
  <id_info>
    <org_study_id>IOP After Bevacizumab</org_study_id>
    <nct_id>NCT00804921</nct_id>
  </id_info>
  <brief_title>Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab</brief_title>
  <official_title>Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab Injection: Preliminary Results</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: To evaluate the effects of anterior chamber paracentesis, brimonidine and oral
      acetazolamide to reduce intra-ocular pressure (IOP) variations after intravitreal bevacizumab
      injection (IVBV).

      Methods: 47 patients scheduled for IVBV (1.5 mg / 0.06 ml) will be randomly assigned to a
      pre-treatment 1 hour before IVBV with either 250 mg oral acetazolamide (DIA, 9 eyes),
      anterior chamber paracentesis immediate after IVBV (PAR, 15 eyes), topic brimonidine
      tartarate 1 hour before IVBV (BRI, 14 eyes), or no pre-treatment IBVB (CTR, 9 eyes). IOP will
      be measured 90 minutes before injection (baseline), just before injection, and at 3, 10, 20
      and 30 minutes after the procedure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Intra-ocular pressure variation after intra-vitreous injection of bevacizumab</measure>
  </primary_outcome>
  <condition>Macular Edema</condition>
  <condition>Diabetic Retinopathy</condition>
  <condition>Macular Degeneration</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>anterior chamber paracentesis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetazolamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brimonidine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  macular edema

        Exclusion Criteria:

          -  pulmonary chronic problems

          -  chronic renal failure

          -  intraocular inflammation

          -  drug or alcohol addiction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>School of Medicine - Clinical Hospital</name>
      <address>
        <city>Ribeirao Preto</city>
        <state>SP</state>
        <zip>14049-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2008</study_first_submitted>
  <study_first_submitted_qc>December 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2008</study_first_posted>
  <last_update_submitted>December 8, 2008</last_update_submitted>
  <last_update_submitted_qc>December 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2008</last_update_posted>
  <responsible_party>
    <name_title>CONEP (Comite Nacional de Etica em Pesquisa)</name_title>
  </responsible_party>
  <keyword>bevacizumab</keyword>
  <keyword>intra-ocular pressure</keyword>
  <keyword>acetazolamide</keyword>
  <keyword>anterior chamber paracentesis</keyword>
  <keyword>brimonidine</keyword>
  <keyword>macular edema secondary to diabetic retinopathy or macular degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Acetazolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

